Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation.

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(De Caterina Raffaele) > (2015-2019) > Effect of apixaban ...

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		04240naa a2200505 4500
001		oai:DiVA.org:uu-374491
003		SwePub
008		190121s2019 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
024	7	a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3744912 URI
024	7	a https://doi.org/10.1136/heartjnl-2018-3133512 DOI
040		a (SwePub)uu
041		a engb eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Christersson, Christinau Uppsala universitet,Institutionen för medicinska vetenskaper,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)chchr086
245	1 0	a Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation.
264		c 2018-09-12
264	1	b BMJ,c 2019
338		a electronic2 rdacarrier
520		a OBJECTIVES: Compare the effect of apixaban and warfarin on coagulation and primary haemostasis biomarkers in atrial fibrillation (AF).METHODS: The biomarker substudy from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial included 4850 patients with AF randomised to treatment with apixaban or warfarin. Sixty per cent of patients used vitamin K antagonist (VKA) within 7 days before randomisation. Prothrombin fragment 1+2 (F1+2), D-dimer, soluble CD40 ligand (sCD40L) and von Willebrand factor (vWF) antigen were analysed at randomisation and after 2 months of study treatment.RESULTS: In patients not on VKA treatment at randomisation, F1+2 and D-dimer levels were decreased by 25% and 23%, respectively, with apixaban, and by 59% and 38%, respectively, with warfarin (p<0.0001 for treatment differences for both). In patients on VKA at randomisation, F1+2 and D-dimer levels increased by 41% and 10%, respectively, with apixaban and decreased by 37% and 11%, respectively, with warfarin (p<0.0001 for treatment differences for both). sCD40L levels were slightly increased at 2 months, regardless of VKA or randomised treatment. Apixaban and warfarin also both reduced vWF antigen regardless of VKA treatment. The efficacy (stroke) and safety (bleeding) of apixaban compared with warfarin was similar irrespectively of biomarker levels at 2 months.CONCLUSIONS: Treatment with apixaban compared with warfarin for stroke prevention in patients with AF was associated with less reduction in thrombin generation and fibrin turnover. This effect of apixaban could contribute to the clinical results where apixaban was superior to warfarin both in stroke prevention and in reducing bleeding risk.TRIAL REGISTRATION NUMBER: NCT00412984.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng
653		a atrial fibrillation
700	1	a Wallentin, Lars,d 1943-u Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi4 aut0 (Swepub:uu)larswall
700	1	a Andersson, Ulrikau Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)ulran224
700	1	a Alexander, John H4 aut
700	1	a Alings, Marco4 aut
700	1	a De Caterina, Raffaele4 aut
700	1	a Gersh, Bernard J4 aut
700	1	a Granger, Christopher B4 aut
700	1	a Halvorsen, Sigrun4 aut
700	1	a Hanna, Michael4 aut
700	1	a Huber, Kurt4 aut
700	1	a Hylek, Elaine M4 aut
700	1	a Lopes, Renato D4 aut
700	1	a Oh, Byung-Hee4 aut
700	1	a Siegbahn, Agneta,d 1947-u Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)agsie424
710	2	a Uppsala universitetb Institutionen för medicinska vetenskaper4 org
773	0	t Heartd : BMJg 105:3, s. 235-242q 105:3<235-242x 1355-6037x 1468-201X
856	4	u https://doi.org/10.1136/heartjnl-2018-313351y Fulltext
856	4	u https://uu.diva-portal.org/smash/get/diva2:1281166/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
856	4	u https://heart.bmj.com/content/heartjnl/105/3/235.full.pdf
856	4 8	u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-374491
856	4 8	u https://doi.org/10.1136/heartjnl-2018-313351

Hitta via bibliotek

Heart (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Christersson, Ch ...; Wallentin, Lars, ...; Andersson, Ulrik ...; Alexander, John ...; Alings, Marco; De Caterina, Raf ...; visa fler...; Gersh, Bernard J; Granger, Christo ...; Halvorsen, Sigru ...; Hanna, Michael; Huber, Kurt; Hylek, Elaine M; Lopes, Renato D; Oh, Byung-Hee; Siegbahn, Agneta ...; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Kardiologi

Artiklar i publikationen: Heart

Av lärosätet: Uppsala universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se